Notice of Results

RNS Number : 9191D

Oxford Biomedica PLC

03 April 2014

 



Oxford BioMedica: Notice of Preliminary Results

Results date: 10 April 2014

Oxford, UK - 03 April 2014: Oxford BioMedica plc (LSE: OXB), the leading gene-based biopharmaceutical company, will be announcing its preliminary results for the twelve months ended 31 December 2013 on Thursday, 10^th April 2014.

An analyst briefing will be held at 09:30am GMT on Thursday, 10th April 2014 at the offices of Consilium Strategic Communications, 41 Lothbury, London, EC2R 7HG. The briefing will be hosted by John Dawson, Chief Executive Officer of Oxford BioMedica and Tim Watts, Chief Financial Officer.

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer		Tel: [phone]
Media Enquiries: Mary-Jane Elliott/Emma Thompson/Matthew Neal Consilium Strategic Communications		Tel: [phone]

Note to editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector^® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Oxford BioMedica has a broad range of partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

END

 

 

NORGMGGDZZMGDZZ